Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Neon Lights Up First PD-1 Combo Study

This article was originally published in Scrip

Executive Summary

The recent biotechnology startup Neon Therapeutics has quickly put its $55m Series A venture capital to work with plans to begin a Phase Ib clinical trial in 2016 for the company's lead immunotherapeutic candidate in combination with the Bristol-Myers Squibb Co. immuno-oncology star Opdivo (nivolumab).


Related Content

Advaxis Advances Personalized Cancer Vaccines With Eye On Manufacturing Time, Cost





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts